Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [Thoracic Oncology]

Conclusion
The safety profile of nivolumab plus PT-DC was consistent with that expected for individual agents; however, treatment discontinuation related to AEs was greater with the combination. Encouraging activity was observed, especially for the nivolumab 5 mg/kg plus paclitaxel-carboplatin group, with a 2-year OS rate of 62%.

Source: Journal of Clinical Oncology - August 23, 2016 Category: Cancer & Oncology Authors: Rizvi, Hellmann, Brahmer, Juergens, Borghaei, Gettinger, Chow, Gerber, Laurie, Goldman, Shepherd, Chen, Shen, Nathan, Harbison, Antonia Tags: Chemotherapy Thoracic Oncology Source Type: research